PURA - Puration Announces Up To $3 Million Anticipated Increase To Original $3 Million Annual Revenue Target
June 07 2017 - 12:01PM
InvestorsHub NewsWire
Dallas, TX - June 7, 2017
- InvestorsHub NewsWire - Puration, Inc. (USOTC:
PURA) today announced that American Cannabis Innovations
Conglomerated (ACI) has completed the acquisition of a controlling
interest in PURA. ACI is a private equity backed rollup
founded to combine a variety of leading young cannabis companies
with complimentary offerings and synergistic operations. PURA is
one of the first of five acquisitions in the cannabis sector ACI
has planned for the near future. ACI is seeking to acquire
early stage, undervalued businesses with intellectual properties
validated by market tests, and commercial or consumer sales.
ACI expects to accelerate the growth of acquired assets and improve
the operating efficiency of acquired assets by improving access to
investment, streamlining redundant functions and leveraging
complimentary functions.
PURA Increase $3 Million Annual Revenue Target &
Extends Operating Reach
PURA has revised its on-demand, online business plan presentation on the
Company’s website with updates to the Company’s plan to achieve $3
million in annual revenue from its cannabis extraction operation.
The revised plan increase is anticipated to add an additional
$1 million to the topline and possibly as much as an additional $3
million in the event pilot product market tests with new extraction
edible and beverage partners go well. The plan also outlines
the Company’s extension into the cannabis tourism industry
initiated earlier this year in an agreement with ML Capital Group
(USOTC:
MLCG).
PURA Market Capitalization Improvements Summary – No
Reverse or Forward Split
The common stock of PURA will remain traded on the OTC Markets with
no forward or reverse split taking place in conjunction with the
ACI transaction. ACI expects the potential for market
capitalizations of PURA to improve by transitioning the Company
toward better investment structures, with better terms, that are
altogether better suited to the current and more mature stage of
development. For instance, PURA recently announced a
substantial convertible debt elimination in
conjunction with the pending ACI transaction in addition to a
$10 million funding
commitment.
Learn More About PURA:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024